WO2022160455A1 - 一种预防及治疗炎症的化合物及其制备方法和应用 - Google Patents

一种预防及治疗炎症的化合物及其制备方法和应用 Download PDF

Info

Publication number
WO2022160455A1
WO2022160455A1 PCT/CN2021/083891 CN2021083891W WO2022160455A1 WO 2022160455 A1 WO2022160455 A1 WO 2022160455A1 CN 2021083891 W CN2021083891 W CN 2021083891W WO 2022160455 A1 WO2022160455 A1 WO 2022160455A1
Authority
WO
WIPO (PCT)
Prior art keywords
take
compound
fractions
elute
pass
Prior art date
Application number
PCT/CN2021/083891
Other languages
English (en)
French (fr)
Inventor
杨理
董文化
梅文莉
戴好富
陈惠琴
魏艳梅
Original Assignee
中国热带农业科学院热带生物技术研究所
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中国热带农业科学院热带生物技术研究所 filed Critical 中国热带农业科学院热带生物技术研究所
Priority to CA3120117A priority Critical patent/CA3120117C/en
Publication of WO2022160455A1 publication Critical patent/WO2022160455A1/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention relates to the technical field of natural medicines, in particular to a compound for preventing and treating inflammation and a preparation method and application thereof.
  • Inflammation itself is a biological defense response, a series of physiological responses such as redness, heat, pain, and dysfunction in order to eliminate harmful stimuli, remove dead cells, and repair damaged tissues. These responses are the immune system. Fundamental behavior in maintaining normal tissue homeostasis during infection and tissue injury. Inflammation is a complex process at the molecular level. During inflammation, macrophages promote the production of pro-inflammatory factors, including tumor necrosis factor (TNF- ⁇ ), various interleukins, prostaglandins (PG), Nitric oxide (NO) and reactive oxygen species (ROS), etc. Studies have shown that asthma, cancer, arthritis and other related chronic degenerative diseases are all associated with the overproduction of these pro-inflammatory mediators.
  • TNF- ⁇ tumor necrosis factor
  • PG prostaglandins
  • NO Nitric oxide
  • ROS reactive oxygen species
  • the technical problem to be solved by the present invention is to provide a compound for preventing and treating inflammation and its preparation method and application, which can inhibit the production of NO and have anti-inflammatory activity.
  • the present invention provides a compound for preventing and treating inflammation, which has the structures shown in formulas I to VIII:
  • the above-mentioned compounds provided by the present invention are isolated from Agarwood sinensis.
  • Aquilaria filaria is the base plant of silk agarwood, which is mainly produced in the Philippines, Indonesia, Papua New Guinea and other places. my country imports a large amount of agarwood from Indonesia every year.
  • the present invention is the first time to separate the above compounds from Agarwood chinensis, and report its anti-inflammatory activity.
  • the present invention provides a method for preparing the compounds represented by the above formulas I to VIII, including:
  • Step 1 After pulverizing the silk agarwood, ultrasonically extract it with an aqueous ethanol solution with a volume fraction of not less than 95% (preferably 6 times of extraction), and the obtained extract is filtered, combined and concentrated to obtain extract A;
  • Step 2 adding water to the extract A to make a suspension, extracting with ethyl acetate and n-butanol in turn, concentrating the ethyl acetate extract to prepare extract B, and concentrating the n-butanol extract to prepare extract C;
  • Step 3 Take extract B, pass through a decompression column (preferably silica gel H), pass through petroleum ether, ethyl acetate (preferably 1:0 ⁇ 5:1, V/V), chloroform, methanol (preferably 1:0 ⁇ 0 : 1, V/V) mixed solution gradient elution, 19 fractions were obtained, recorded as Fr.1 ⁇ Fr.19;
  • Step 5 Take Fr.11-2, pass it through a reversed-phase column, and elute with a gradient of 30% to 100% methanol aqueous solution to obtain 30 fractions, denoted as Fr.11-2-1 to Fr.11-2-30 ;
  • Step 6 Take Fr.11-2-1 and purify by semi-preparative HPLC (preferably C18 chromatographic column, 60% methanol-water elution) to obtain the compound of formula VIII;
  • Step 7 Take Fr.13, pass through MCI column, and elute with a gradient of 30%-100% methanol aqueous solution to obtain 4 fractions, denoted as Fr.13-1 ⁇ Fr.13-4;
  • Step 8 Take Fr.13-1, pass it through a reversed-phase column, and elute with a gradient of 30% to 100% methanol aqueous solution to obtain 15 fractions, denoted as Fr.13-1-1 to Fr.13-1-15 ;
  • Step 9 Take Fr.13-1-8, pass through a Sephadex column, and elute with methanol to obtain 4 fractions, denoted as Fr.13-1-8-1 ⁇ Fr.13-1- 8-4;
  • Step 10 Take Fr.13-1-8-4, pass it through a silica gel column, and elute with a gradient of chloroform:ethyl acetate to obtain 5 fractions, denoted as Fr.13-1-8-4-1 ⁇ Fr. 13-1-8-4-5;
  • Step 11 Take Fr.13-1-8-4-1 and purify by semi-preparative HPLC (preferably C18 column, 34% acetonitrile-water elution) to obtain the compound of formula V;
  • Step 12 Take Fr.13-1-8-4-2 and purify by semi-preparative HPLC (preferably C18 column, 36% acetonitrile-water elution) to obtain the compound of formula III;
  • Step 13 Take Fr.13-1-7, pass it through a Sephadex column, and elute with methanol to obtain 4 fractions, denoted as Fr.13-1-7-1 ⁇ Fr.13-1- 7-4;
  • Step 14 Take Fr.13-1-7-4, pass it through a silica gel column, and elute with a gradient of petroleum ether: ethyl acetate to obtain 6 fractions, denoted as Fr.13-1-7-4-1 ⁇ Fr .13-1-7-4-6;
  • Step 15 Take Fr.13-1-7-4-1 and purify by semi-preparative HPLC (preferably C18 chromatographic column, 47% methanol-water elution) to obtain the compound of formula IV;
  • Step 17 Take Fr.13-1-10-5, pass it through a silica gel column, and elute with a gradient of petroleum ether: ethyl acetate to obtain 22 fractions, denoted as Fr.13-1-10-5-1 ⁇ Fr. 13-1-10-5-22;
  • Step 18 Take Fr.13-1-10-5-16, purify by semi-preparative HPLC (preferably C18 chromatographic column, 33% acetonitrile-water elution) to obtain the compound of formula VII;
  • Step 19 Take Fr.13-1-10-4, pass through a Sephadex column, and elute with methanol to obtain 3 fractions, denoted as Fr.13-1-10-4-1 ⁇ Fr. 13-1-10-4-3;
  • Step 20 Take Fr.13-1-10-4-2, pass it through a silica gel column, and elute with a gradient of chloroform: methanol to obtain 15 fractions, which are recorded as Fr.13-1-10-4-2-1 ⁇ Fr .13-1-10-4-2-15;
  • Step 21 Take Fr.13-1-10-4-2-7 and purify by semi-preparative HPLC (preferably C18 column, 50% acetonitrile-water elution) to obtain the compound of formula I;
  • Step 22 Take Fr.15, pass it through a reversed-phase column, and elute with a gradient of 30% to 100% methanol aqueous solution to obtain 45 fractions, denoted as Fr.15-1 to Fr.15-45;
  • Step 23 Take Fr.15-20, pass it through a Sephadex column, and elute with methanol to obtain 3 fractions, denoted as Fr.15-20-1 ⁇ Fr.15-20-3;
  • Step 24 Take Fr.15-20-3 and purify by semi-preparative HPLC (preferably C18 chromatographic column, 25% acetonitrile-water elution) to obtain the compound of formula VI;
  • Step 25 Take Fr.15-17, pass it through a Sephadex column, and elute with methanol to obtain 2 fractions, denoted as Fr.15-17-1 ⁇ Fr.15-17-2;
  • Step 26 Take Fr.15-17-2, pass through a silica gel column, and elute with a gradient of chloroform:ethyl acetate to obtain 7 fractions, denoted as Fr.15-17-2-1 ⁇ Fr.15-17- 2-7;
  • Step 27 Take Fr.15-17-2-5 and purify by semi-preparative HPLC (preferably C18 chromatographic column, 36% methanol-water elution) to obtain the compound of formula II.
  • the present invention uses LPS-induced RAW264.7 to produce NO as a model to evaluate the anti-inflammatory activity, and the results show that the compound represented by formula I-VIII can effectively inhibit the production of NO, reflecting the anti-inflammatory activity.
  • the RAW264.7 is a mouse mononuclear macrophage leukemia cell.
  • the LPS is lipopolysaccharide, which is the main component of the cell wall of Gram-negative bacteria.
  • the present invention provides the application of the above compound or the compound prepared by the above preparation method for inhibiting the production of pro-inflammatory factors.
  • the pro-inflammatory factor includes one of tumor necrosis factor (TNF- ⁇ ), various interleukins, prostaglandins (PG), nitric oxide (NO), reactive oxygen species (ROS), etc. or variety.
  • TNF- ⁇ tumor necrosis factor
  • PG prostaglandins
  • NO nitric oxide
  • ROS reactive oxygen species
  • the present invention provides the use of the above compound or the compound prepared by the above preparation method as an NO production inhibitor.
  • the present invention provides the application of the above compound or the compound prepared by the above preparation method in preparing a medicine for preventing, treating or alleviating inflammation or inflammatory reaction.
  • the inflammatory response includes: one or more of body redness, swelling, heat, and pain.
  • the present invention provides a medicament for preventing, treating or alleviating inflammation or inflammatory response, comprising one or more of the compounds represented by formulas I to VIII, and a pharmaceutically acceptable adjuvant;
  • the pharmaceutically acceptable adjuvants include fruit powder, edible flavors, sweeteners, sour agents, fillers, lubricants, preservatives, suspending agents, food colorings, diluents, emulsifiers, disintegrating agents One or a mixture of two or more of decomposers or plasticizers.
  • the dosage form of the medicine is an oral preparation, more preferably a tablet, capsule, pill, granule, decoction, ointment, lotion, oral liquid, drop pill or syrup.
  • the capsules are hard capsules or soft capsules.
  • the tablet is an oral tablet or a buccal tablet. More preferably, the oral tablet refers to a tablet for oral administration. Most of the drugs in such tablets are absorbed through the gastrointestinal tract to exert their effects, and some drugs in the tablets also exert their effects locally in the gastrointestinal tract.
  • the oral tablet is an ordinary compressed tablet, a dispersible tablet, an effervescent tablet, a chewable tablet, a coated tablet or a sustained-release tablet.
  • the present invention also provides a method for treating inflammation by administering the medicament of the present invention.
  • the present invention also provides a food for preventing, treating or alleviating inflammation or inflammatory response, comprising one or more of the compounds represented by formulas I to VIII;
  • the present invention provides a compound for preventing and treating inflammation, which has the structures shown in formulas I to VIII, and belongs to 2-(2-phenylethyl) chromones.
  • the compounds represented by formulas I to VIII can inhibit the production of NO and reflect the anti-inflammatory activity. Therefore, it is shown that the above-mentioned compounds can be used to prepare foods and/or medicines for preventing, treating and/or alleviating inflammation.
  • Fig. 1 is the 1 H NMR spectrum of the compound represented by formula (I);
  • Figure 2 is the 13 C NMR spectrum of the compound represented by formula (I);
  • Fig. 3 is the HSQC spectrum of the compound represented by formula (I);
  • Fig. 4 is the 1 H- 13 C HMBC spectrum of the compound represented by formula (I);
  • Figure 5 is the 1 H- 1 H COSY spectrum of the compound represented by formula (I);
  • Fig. 6 is the ROESY spectrum of the compound represented by formula (I);
  • Figure 7 is the 1 H NMR spectrum of the compound represented by formula (II);
  • Figure 8 is the 13 C NMR spectrum of the compound represented by formula (II);
  • Fig. 9 is the HSQC spectrum of the compound represented by formula (II);
  • Figure 10 is the 1 H- 13 C HMBC spectrum of the compound represented by the formula (II);
  • Figure 11 is the 1 H- 1 H COSY spectrum of the compound represented by the formula (II);
  • Figure 12 is the ROESY spectrum of the compound represented by formula (II);
  • Figure 13 is the 1 H NMR spectrum of the compound represented by formula (III);
  • Figure 14 is the 13 C NMR spectrum of the compound represented by formula (III);
  • Figure 15 is the HSQC spectrum of the compound represented by formula (III);
  • Figure 16 is the 1 H- 13 C HMBC spectrum of the compound represented by the formula (III);
  • Figure 17 is the 1 H- 1 H COSY spectrum of the compound represented by formula (III);
  • Figure 18 is the ROESY spectrum of the compound represented by formula (III);
  • Figure 19 is the 1 H NMR spectrum of the compound represented by formula (IV);
  • Figure 20 is the 13 C NMR spectrum of the compound represented by formula (IV);
  • Figure 21 is the HSQC spectrum of the compound represented by formula (IV).
  • Figure 22 is the 1 H- 13 C HMBC spectrum of the compound represented by formula (IV);
  • Figure 23 is the 1 H- 1 H COSY spectrum of the compound represented by formula (IV);
  • Figure 24 is the ROESY spectrum of the compound represented by formula (IV);
  • Figure 25 is the 1 H NMR spectrum of the compound represented by formula (V);
  • Figure 26 is the 13 C NMR spectrum of the compound represented by formula (V);
  • Figure 27 is the HSQC spectrum of the compound represented by formula (V);
  • Figure 28 is the 1 H NMR spectrum of the compound represented by formula (VI);
  • Figure 29 is the 13 C NMR spectrum of the compound represented by formula (VI);
  • Figure 30 is the HSQC spectrum of the compound represented by formula (VI);
  • Figure 31 is the 1 H NMR spectrum of the compound represented by formula (VII);
  • Figure 32 is the 13 C NMR spectrum of the compound represented by formula (VII);
  • Figure 33 is the HSQC spectrum of the compound represented by formula (VII);
  • Figure 34 is the 1 H NMR spectrum of the compound represented by formula (VIII);
  • Figure 35 is the 13 C NMR spectrum of the compound represented by formula (VIII);
  • Figure 36 is the HSQC spectrum of the compound represented by formula (VIII);
  • Figure 37 is a schematic diagram of1H- 1H COSY and key1H - 13C HMBC of compounds provided by the present invention.
  • test materials used in the present invention are all common commercial products and can be purchased in the market.
  • N-1000 (2L) vertical rotary evaporator and CA-1111 cooling water circulation device (Shanghai Airon Instrument Co., Ltd.);
  • SHZ-D(III) circulating vacuum pump (Shanghai Longtuo Instrument Equipment Co., Ltd.);
  • the silk agarwood is pulverized into powder, it is ultrasonically extracted for 6 times by using an aqueous ethanol solution of more than 95%, and the obtained extract is filtered, combined and concentrated to form an extract. Then, water was added and stirred to form a suspension, which was successively extracted with ethyl acetate and n-butanol, and each extraction layer was extracted until the extract was colorless. Each extraction layer was evaporated and concentrated to prepare an extract for use.
  • Fr.13 in it was passed through an MCI column and eluted with a gradient of 30% to 100% methanol aqueous solution to obtain 4 fractions, denoted as Fr.13-1 to Fr.13-4.
  • Fr.13-1 was taken, passed through a reversed-phase column, and eluted with a gradient of 30% to 100% methanol aqueous solution to obtain 15 fractions, which were recorded as Fr.13-1-1 to Fr.13-1-15.
  • Fr.13-1-8 pass through a Sephadex column, and elute with methanol to obtain 4 fractions, which are recorded as Fr.13-1-8-1 ⁇ Fr.13-1-8-4 ;
  • Fr.13-1-7 pass through a Sephadex column, and elute with methanol to obtain 4 fractions, which are recorded as Fr.13-1-7-1 ⁇ Fr.13-1-7-4 ;
  • Fr.13-1-10-4 pass through a Sephadex column, and elute with methanol to obtain 3 fractions, denoted as Fr.13-1-10-4-1 ⁇ Fr.13-1 -10-4-3;
  • Fr.13-1-10-4-2 pass it through a silica gel column, and elute with a gradient of chloroform: methanol (1:0-0:1) to obtain 15 fractions, which are recorded as Fr. 13-1-10-4-2-1 ⁇ Fr.13-1-10-4-2-15;
  • SW-40 ultra-clean workbench (Shanghai Boxun Industrial Co., Ltd. Medical Equipment Factory);
  • Fetal bovine serum FBS, DMEM medium were purchased from Gibco, USA;
  • Indomethacin was purchased from Sigma Company.
  • the control group was indomethacin
  • the negative control group was DMSO
  • the compounds to be tested were doubling and half-diluting with 5 concentration gradients.
  • the abscissa represents the concentration of the tested compound
  • the ordinate represents the inhibition rate
  • the IC 50 value of the tested compound is obtained by plotting.
  • Inhibition rate (%) (C 2 -C 1 )/(C 2 -C 0 ) ⁇ 100%;
  • C 0 , C 1 , and C 2 are the absorbance values of the blank control group (without LPS), the experimental group, and the negative (with LPS) control group measured at 540 nm, respectively.
  • the inhibition rate at each concentration was calculated and the compound concentration-inhibition rate curve was drawn, and the half-inhibitory concentration (IC 50 value) of the compound on LPS-induced NO production in RAW264.7 was calculated.
  • the results are shown in Table 3. It can be seen that the above compounds can effectively inhibit the production of NO in RAW264.7 cells, exhibit a certain anti-inflammatory activity and have a significant effect, which is better than the positive control indomethacin.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及天然药物领域，具体提供了一种预防及治疗炎症的化合物，具有式Ⅰ～Ⅷ所示结构，属2-(2-苯乙基)色酮类化合物。以LPS诱导RAW264.7产生NO为模型进行抗炎活性评价，式I～Ⅷ所示的化合物能够抑制NO的产生，体现抗炎活性。因此表明上述化合物能够用于制备预防、治疗和/或缓解炎症的食品和/或药品。

Description

一种预防及治疗炎症的化合物及其制备方法和应用
本申请要求于2021年01月27日提交中国专利局、申请号为202110113002.1、发明名称为“一种预防及治疗炎症的化合物及其制备方法和应用”的中国专利申请的优先权，其全部内容通过引用结合在本申请中。
技术领域
本发明涉及天然药物技术领域，尤其涉及一种预防及治疗炎症的化合物及其制备方法和应用。
背景技术
炎症本身是一种生物防御反应，为了消除有害刺激、清除坏死的细胞、并修复受损的组织而产生的一系列生理反应，例如红肿、发热、疼痛以及功能障碍等等，这些反应是免疫系统在感染和组织损伤过程中维持正常组织稳态的基本行为。炎症在分子水平上是一个复杂的过程，炎症期间由巨噬细胞促进产生促炎因子，所述促炎因子包括肿瘤坏死因子(TNF-α)，各种白细胞介素，前列腺素(PG)，一氧化氮(NO)和活性氧(ROS)等。研究表明哮喘，癌症，关节炎和其他相关的慢性退行性疾病均与这些促炎介质的过量产生有关。为了治愈炎症性疾病，需要调节整个过程中分泌的各种化学介质的产生。世界范围内，最常见的用于炎症和相关疾病的药物代表有阿司匹林、吲哚美辛、布洛芬、酮洛芬、氟比洛芬等。然而，现有的炎症药物并非在所有病例中都有效，而且长期服用这些药物会引起一些不良反应，如失眠、呕吐、头痛、高血压等。因此，有必要寻找新的抗炎活性物质，为新型抗炎药物的研发提供先导物。
发明内容
有鉴于此，本发明要解决的技术问题在于提供一种预防及治疗炎症的化合物及其制备方法和应用，能够抑制NO的产生，具有抗炎活性。
为达到上述目的，本发明提供了一种预防及治疗炎症的化合物，具有式Ⅰ～Ⅷ所示结构：
Figure PCTCN2021083891-appb-000001
本发明提供的上述化合物分离自丝沉香。丝沉香的基源植物为Aquilaria filaria，主要产于菲律宾、印度尼西亚、巴布亚新几内亚等地。我国每年从印度尼西亚进口大量的丝沉香，然而丝沉香的化学成分和生物活性目前未见报道，且没有抗炎活性的报道。本发明首次从丝沉香中分离得到上述化合物，并报道了其抗炎活性。
本发明提供了上述式I～Ⅷ所示化合物的制备方法，包括：
步骤1：将丝沉香粉碎后，以体积分数不低于95％的乙醇水溶液超声提取(优选提取6次)，所得浸提液过滤后合并浓缩得浸膏A；
步骤2：将所述浸膏A加水制成混悬液，依次用乙酸乙酯和正丁醇进行萃取，将乙酸乙酯萃取液浓缩制成浸膏B，正丁醇萃取液浓缩制成浸膏C；
步骤3：取浸膏B，过减压柱(优选硅胶H)，经石油醚、乙酸乙酯(优选1:0→5:1,V/V)以及氯仿、甲醇(优选1:0→0:1,V/V)的混合液梯度洗脱，获得19个流分，记为Fr.1～Fr.19；
步骤4：取Fr.11，过葡聚糖凝胶柱，以甲醇：氯仿＝1：1的混合液进行洗脱，得到3个流份，记为Fr.11-1～Fr.11-3；
步骤5：取Fr.11-2，过反相柱，以30％～100％甲醇水溶液梯度洗脱，得到30个流份，记为Fr.11-2-1～Fr.11-2-30；
步骤6：取Fr.11-2-1，经半制备HPLC(优选C18色谱柱，60％甲醇-水洗脱)纯化，得到式Ⅷ化合物；
步骤7：取Fr.13，过MCI柱，以30％～100％甲醇水溶液梯度洗脱，得到4个流份，记为Fr.13-1～Fr.13-4；
步骤8：取Fr.13-1，过反相柱，以30％～100％甲醇水溶液梯度洗脱，得到15个流份，记为Fr.13-1-1～Fr.13-1-15；
步骤9：取Fr.13-1-8，过葡聚糖凝胶柱，以甲醇进行洗脱，得到4个流份，记为Fr.13-1-8-1～Fr.13-1-8-4；
步骤10：取Fr.13-1-8-4，过硅胶柱，以氯仿：乙酸乙酯梯度洗脱，得到5个流份，记为Fr.13-1-8-4-1～Fr.13-1-8-4-5；
步骤11：取Fr.13-1-8-4-1，经半制备HPLC(优选C18色谱柱，34％乙腈-水洗脱)纯化，得到式Ⅴ化合物；
步骤12：取Fr.13-1-8-4-2，经半制备HPLC(优选C18色谱柱，36％乙腈-水洗脱)纯化，得到式Ⅲ化合物；
步骤13：取Fr.13-1-7，过葡聚糖凝胶柱，以甲醇进行洗脱，得到4个流份，记为Fr.13-1-7-1～Fr.13-1-7-4；
步骤14：取Fr.13-1-7-4，过硅胶柱，以石油醚：乙酸乙酯梯度洗脱，得到6个流份，记为Fr.13-1-7-4-1～Fr.13-1-7-4-6；
步骤15：取Fr.13-1-7-4-1，经半制备HPLC(优选C18色谱柱，47％甲醇-水洗脱)纯化，得到式Ⅳ化合物；
步骤16：取Fr.13-1-10，过葡聚糖凝胶柱，以甲醇：氯仿＝1：1的混合液进行洗脱，得到5个流份，记为Fr.13-1-10-1～Fr.13-1-10-5；
步骤17：取Fr.13-1-10-5，过硅胶柱，以石油醚：乙酸乙酯梯度洗脱得到22个流份，记为Fr.13-1-10-5-1～Fr.13-1-10-5-22；
步骤18：取Fr.13-1-10-5-16，经半制备HPLC(优选C18色谱柱，33％乙腈-水洗脱)纯化，得到式Ⅶ化合物；
步骤19：取Fr.13-1-10-4，过葡聚糖凝胶柱，以甲醇进行洗脱，得到3个流份，记为Fr.13-1-10-4-1～Fr.13-1-10-4-3；
步骤20：取Fr.13-1-10-4-2，过硅胶柱，以氯仿：甲醇梯度洗脱得到15个流份，记为Fr.13-1-10-4-2-1～Fr.13-1-10-4-2-15；
步骤21：取Fr.13-1-10-4-2-7，经半制备HPLC(优选C18色谱柱，50％乙腈-水洗脱)纯化，得到式Ⅰ化合物；
步骤22：取Fr.15，过反相柱，以30％～100％甲醇水溶液梯度洗脱，得到45个流份，记为Fr.15-1～Fr.15-45；
步骤23：取Fr.15-20，过葡聚糖凝胶柱，以甲醇进行洗脱，得到3个流份，记为Fr.15-20-1～Fr.15-20-3；
步骤24：取Fr.15-20-3，经半制备HPLC(优选C18色谱柱，25％乙腈-水洗脱)纯化，得到式Ⅵ化合物；
步骤25：取Fr.15-17，过葡聚糖凝胶柱，以甲醇进行洗脱，得到2个流份，记为Fr.15-17-1～Fr.15-17-2；
步骤26：取Fr.15-17-2，经硅胶柱，以氯仿：乙酸乙酯梯度洗脱，得到7个流份，记为Fr.15-17-2-1～Fr.15-17-2-7；
步骤27：取Fr.15-17-2-5，经半制备HPLC(优选C18色谱柱，36％甲醇-水洗脱)纯化，得到式Ⅱ化合物。
本发明以LPS诱导RAW264.7产生NO为模型进行抗炎活性评价，结果表明，式I-Ⅷ所示的化合物可有效抑制NO的产生，体现抗炎活性。
本发明中，所述RAW264.7为小鼠单核巨噬细胞白血病细胞。
所述LPS为脂多糖，是革兰氏阴性细菌细胞壁的主要成分。
基于此，本发明提供了上述化合物或上述制备方法制备的化合物抑制产生促炎因子的应用。
本发明优选的，所述促炎因子包括肿瘤坏死因子(TNF-α)、各种白细胞介素、前列腺素(PG)、一氧化氮(NO)、活性氧(ROS)等中的一种或多种。
本发明提供了上述化合物或上述制备方法制备的化合物作为NO生成抑制剂的应用。
本发明提供了上述化合物或上述制备方法制备的化合物在制备预防、治疗或缓解炎症或炎症反应的药物中的应用。
本发明优选的，所述炎症反应包括：机体发红、肿胀、发热、疼痛中的一种或多种。
本发明提供了一种预防、治疗或缓解炎症或炎症反应的药物，包括式Ⅰ～Ⅷ所示化合物中的一个或多个，以及药学上可接受的辅剂；
Figure PCTCN2021083891-appb-000002
本发明优选的，所述药学上可接受的辅料包括水果粉、食用香精、甜味剂、酸味剂、填充剂、润滑剂、防腐剂、助悬剂、食用色素、稀释剂、乳化剂、崩解剂或增塑剂等中的一种或两者以上的混合物。
本发明优选的，所述药物的剂型为口服制剂，更优选为片剂、胶囊剂、丸剂、颗粒剂、汤剂、膏剂、露剂、口服液剂、滴丸剂或糖浆剂。
更优选的，所述胶囊剂为硬胶囊剂或软胶囊剂。更优选的，所述片剂为口服片剂或口腔片剂。更优选的，所述口服片剂指供口服的片剂，多数此类片剂中的药物是经胃肠道吸收而发挥作用，也有的片剂中的药物是在胃肠道局部发挥作用。在本发明提供的一些实施例中，口服片剂为普通压制片、分散片、泡腾片、咀嚼片、包衣片或缓控释片。
本发明还提供了一种治疗炎症的方法，其为给予本发明所述的药物。
本发明还提供了一种预防、治疗或缓解炎症或炎症反应的食品，包括式Ⅰ～Ⅷ所示化合物中的一个或多个；
Figure PCTCN2021083891-appb-000003
与现有技术相比，本发明提供了一种预防及治疗炎症的化合物，具有式Ⅰ～Ⅷ所示结构，属2-(2-苯乙基)色酮类化合物。以LPS诱导RAW264.7产生NO为模型进行抗炎活性评价，式I～Ⅷ所示的化合物能够抑制NO的产生，体现抗炎活性。因此表明上述化合物能够用于制备预防、治疗和/或缓解炎症的食品和/或药品。
附图说明
图1是式(Ⅰ)所示化合物的 1H NMR图谱；
图2是式(Ⅰ)所示化合物的 13C NMR图谱；
图3是式(Ⅰ)所示化合物的HSQC图谱；
图4是式(Ⅰ)所示化合物的 1H- 13C HMBC图谱；
图5是式(Ⅰ)所示化合物的 1H- 1H COSY图谱；
图6是式(Ⅰ)所示化合物的ROESY图谱；
图7是式(Ⅱ)所示化合物的 1H NMR图谱；
图8是式(Ⅱ)所示化合物的 13C NMR图谱；
图9是式(Ⅱ)所示化合物的HSQC图谱；
图10是式(Ⅱ)所示化合物的 1H- 13C HMBC图谱；
图11是式(Ⅱ)所示化合物的 1H- 1H COSY图谱；
图12是式(Ⅱ)所示化合物的ROESY图谱；
图13是式(Ⅲ)所示化合物的 1H NMR图谱；
图14是式(Ⅲ)所示化合物的 13C NMR图谱；
图15是式(Ⅲ)所示化合物的HSQC图谱；
图16是式(Ⅲ)所示化合物的 1H- 13C HMBC图谱；
图17是式(Ⅲ)所示化合物的 1H- 1H COSY图谱；
图18是式(Ⅲ)所示化合物的ROESY图谱；
图19是式(Ⅳ)所示化合物的 1H NMR图谱；
图20是式(Ⅳ)所示化合物的 13C NMR图谱；
图21是式(Ⅳ)所示化合物的HSQC图谱；
图22是式(Ⅳ)所示化合物的 1H- 13C HMBC图谱；
图23是式(Ⅳ)所示化合物的 1H- 1H COSY图谱；
图24是式(Ⅳ)所示化合物的ROESY图谱；
图25是式(Ⅴ)所示化合物的 1H NMR图谱；
图26是式(Ⅴ)所示化合物的 13C NMR图谱；
图27是式(Ⅴ)所示化合物的HSQC图谱；
图28是式(Ⅵ)所示化合物的 1H NMR图谱；
图29是式(Ⅵ)所示化合物的 13C NMR图谱；
图30是式(Ⅵ)所示化合物的HSQC图谱；
图31是式(Ⅶ)所示化合物的 1H NMR图谱；
图32是式(Ⅶ)所示化合物的 13C NMR图谱；
图33是式(Ⅶ)所示化合物的HSQC图谱；
图34是式(Ⅷ)所示化合物的 1H NMR图谱；
图35是式(Ⅷ)所示化合物的 13C NMR图谱；
图36是式(Ⅷ)所示化合物的HSQC图谱；
图37是本发明提供的化合物的 1H- 1H COSY和关键的 1H- 13C HMBC示意图。
具体实施方式
为了进一步说明本发明，下面结合实施例对本发明提供的领域，尤其涉及一种预防及治疗炎症的化合物及其制备方法和应用进行详细描述。
本领域技术人员可以借鉴本文内容，适当改进工艺参数实现。特别需要指出的是，所有类似的替换和改动对本领域技术人员来说是显而易见的，它们都被视为包括在本发明。本发明的方法及应用已经通过较佳实施例进行了描述，相关人员明显能在不脱离本发明内容、精神和范围内对本文的方法和应用进行改动或适当变更与组合，来实现和应用本发明技术。
本发明采用的试材皆为普通市售品，皆可于市场购得。
实施例1
1.1仪器与试剂
Bruker AV-500型超导核磁共振波谱仪(瑞士Bruker公司)；
Autospec300质谱仪(英国VG公司)；
分析型高效液相色谱仪(美国Agilent公司)；
半制备高效液相色谱仪(美国Dionex公司)；
N-1000(2L)立式旋转蒸发仪和CA-1111冷却水循环装置(上海爱朗仪器有限公司)；
SHZ-D(Ⅲ)循环真空泵(上海隆拓仪器设备有限公司)；
AS 220.R2万分之一电子秤(RADWAG Wagi Elektroniczne)；
Sephadex LH-20凝胶(Merck Co.Ltd)；
C18反相硅胶(20～45μm，日本Fuji Silysia Chemical Ltd公司)；
柱层析用硅胶和薄层层析硅胶板(青岛海洋化工厂)；
氘代试剂和色谱甲醇(德国Merck公司)；
95％乙醇、重蒸甲醇、乙酸乙酯、氯仿、石油醚、丙酮等常用有机试剂(天津科密欧、天津福晨、广州光华等公司)。
1.2化合物的制备和结构鉴定
取丝沉香粉碎成粉末后，采用95％以上的乙醇水溶液超声提取6次，所得浸提液过滤后合并浓缩成浸膏。之后加水搅拌制成混悬液，依次用乙酸乙酯、正丁醇进行萃取，各萃取层萃取至萃取液无色。各萃取层蒸发浓缩制成浸膏待用。
取乙酸乙酯层浸膏，过减压柱(硅胶H)，采用石油醚：乙酸乙酯(1:0→5:1,V/V)和氯仿：甲醇(1:0→0:1,V/V)系统梯度洗脱，并将所得馏分分别点板浓缩合并，得到19个流分(Fr.1～Fr.19)。
将其中Fr.11，过葡聚糖凝胶柱，以甲醇：氯仿＝1：1的混合液进行洗脱，得到3个流份，记为Fr.11-1～Fr.11-3；取Fr.11-2，过反相柱，以30％～100％甲醇水溶液梯度洗脱，得到30个流份，记为Fr.11-2-1～Fr.11-2-30；取Fr.11-2-1，经半制备HPLC(C18色谱柱，60％甲醇-水洗脱)纯化，得到式Ⅷ化合物(tR＝15.0min)。
将其中的Fr.13，过MCI柱，以30％～100％甲醇水溶液梯度洗脱，得到4个流份，记为Fr.13-1～Fr.13-4。取Fr.13-1，过反相柱，以30％～100％甲醇水溶液梯度洗脱，得到15个流份，记为Fr.13-1-1～Fr.13-1-15。取Fr.13-1-8，过葡聚糖凝胶柱，以甲醇进行洗脱，得到4个流份，记为Fr.13-1-8-1～Fr.13-1-8-4；取Fr.13-1-8-4，过硅胶柱，以氯仿：乙酸乙酯(60：1)梯度洗脱，得到5个流份，记为Fr.13-1-8-4-1～Fr.13-1-8-4-5；取Fr.13-1-8-4-1，经半制备HPLC(C18色谱柱，34％乙腈-水洗脱)纯化，得到式Ⅴ化合物(tR＝16.5min)。
取Fr.13-1-8-4-2，经半制备HPLC(C18色谱柱，36％乙腈-水洗脱)纯化，得到式Ⅲ化合物(tR＝10.0min)。
取Fr.13-1-7，过葡聚糖凝胶柱，以甲醇进行洗脱，得到4个流份，记为Fr.13-1-7-1～Fr.13-1-7-4；取Fr.13-1-7-4，过硅胶柱，以石油醚：乙酸乙酯(10：1)梯度洗脱，得到6个流份，记为Fr.13-1-7-4-1～Fr.13-1-7-4-6；取Fr.13-1-7-4-1，经半制备HPLC(C18色谱柱，47％甲醇-水洗脱)纯化，得到式Ⅳ化合物(tR＝26min)。
取Fr.13-1-10，过葡聚糖凝胶柱，以甲醇：氯仿＝1：1的混合液进行洗脱，得到5个流份，记为Fr.13-1-10-1～Fr.13-1-10-5；取Fr.13-1-10-5，过硅胶柱，以石油醚：乙酸乙酯(12：1)梯度洗脱得到22个流份，记为Fr.13-1-10-5-1～Fr.13-1-10-5-22；取Fr.13-1-10-5-16，经半制备HPLC(C18色谱柱，33％乙腈-水洗脱)纯化，得到式Ⅶ化合物(tR＝53.2min)；
取Fr.13-1-10-4，过葡聚糖凝胶柱，以甲醇进行洗脱，得到3个流份，记为Fr.13-1-10-4-1～Fr.13-1-10-4-3；取Fr.13-1-10-4-2，过硅胶柱，以氯仿：甲醇(1：0–0：1)梯度洗脱得到15个流份，记为Fr.13-1-10-4-2-1～Fr.13-1-10-4-2-15；取Fr.13-1-10-4-2-7，经半制备HPLC(C18色谱柱，50％乙腈-水洗脱)纯化，得到式Ⅰ化合物(tR＝35.5min)。
将其中的Fr.15，过反相柱，以30％～100％甲醇水溶液梯度洗脱，得到45个流份，记为Fr.15-1～Fr.15-45；取Fr.15-20，过葡聚糖凝胶柱，以甲醇进行洗脱，得到3个流份，记为Fr.15-20-1～Fr.15-20-3；取Fr.15-20-3，经半制备HPLC(C18色谱柱，25％乙腈-水洗脱)纯化，得到式Ⅵ化合物(tR＝25.0min)。
取Fr.15-17，过葡聚糖凝胶柱，以甲醇进行洗脱，得到2个流份，记为Fr.15-17-1～Fr.15-17-2；取Fr.15-17-2，经硅胶柱，以氯仿：乙酸乙酯(10:1–1:1体积比)梯度洗脱，得到7个流份，记为Fr.15-17-2-1～Fr.15-17-2-7；取Fr.15-17-2-5，经半制备HPLC(C18色谱柱，36％甲醇-水洗脱)纯化，得到式Ⅱ化合物(tR＝42.5min)。
化合物结构如下：
Figure PCTCN2021083891-appb-000004
式I-Ⅷ所示结构鉴定图谱如图1～图37所示。
式I-Ⅷ所示结构鉴定数据如表1、表2所示：
表1.式I-Ⅷ所示化合物的质谱和分子式
化合物 质谱 分子式
Ⅰ 581.1824[M–H] – C 34H 30O 9
Ⅱ 405.0688[M+Na] + C 18H 19ClO 7
Ⅲ 297.0733[M–H] – C 17H 14O 5
Ⅳ 297.0767[M–H] – C 17H 14O 5
Ⅴ 351.1[M+Na] + C 18H 16O 6
Ⅵ 289.1[M+Na] + C 17H 14O 3
Ⅶ 319.4[M+Na] + C 18H 16O 4
Ⅷ 333.2[M+Na] + C 19H 18O 4
1H NMR(500MHz)和 13C NMR(125MHz)数据如表2所示：
表2.式I-Ⅳ所示化合物的NMR数据(溶剂为氘代甲醇)
Figure PCTCN2021083891-appb-000005
Figure PCTCN2021083891-appb-000006
以上数据以及图谱验证了上述化合物结构。
实施例2：式I-Ⅷ化合物抗炎活性评价
2.1仪器与材料
小鼠单核巨噬细胞白血病细胞(RAW264.7)、非洲绿猴肾细胞(Vero)由中国科学院干细胞库提供；
SW-40超净工作台(上海博讯实业有限公司医疗设备厂)；
CO 2培养箱(英国RS Biotech公司)；
ELX-800酶标仪(美国宝特公司)；
胎牛血清FBS，DMEM培养液购自Gibco，USA；
3-(4,5-二甲基噻唑-2)-2,5-二苯基四氮唑溴盐(MTT)购自amresco，USA；
吲哚美辛购自Sigma公司。
2.2抗炎活性评价
选取RAW264.7(小鼠单核巨噬细胞白血病细胞)，在96孔平底细胞培养板上接种100μL浓度为5×10 4个/mL的细胞，培养于37℃，5％CO 2，90％以上湿度的条件下，24h后加入50μL配制好的待测化合物溶液，继续在该条件下培养，1h后加入50μL配制的LPS(终浓度500ng/mL)溶液，24h后每孔取上清100μL于新的96孔板中，之后向每孔加入100μL(40mg/mL)的Griess试剂，十字交叉法混匀。于酶标仪540nm波长下测定并记录每孔的吸光度， 按下面公式计算NO抑制率。对照组为吲哚美辛，阴性对照组为DMSO，把待测化合物倍半稀释5个浓度梯度。用横坐标表示待测化合物浓度，纵坐标表示抑制率，作图求出待测化合物的IC 50值。
抑制率(％)＝(C 2-C 1)/(C 2-C 0)×100％；
式中：C 0、C 1、C 2分别为540nm下测得的空白对照组(不加LPS)、实验组、阴性(加LPS)对照组的吸光值。计算各浓度下的抑制率并绘制化合物浓度—抑制率曲线图，计算得到化合物对LPS诱导RAW264.7产生NO的半抑制浓度(IC 50值)。结果如表3所示，可以看出，上述化合物能有效抑制RAW264.7细胞NO的产生量，表现出一定的抗炎活性且效果显著，优于阳性对照吲哚美辛。
表3 化合物对RAW264.7产生NO的抑制作用
测试样品 IC 50±SD(μM)
吲哚美辛(阳性对照) 52.30±2.11
化合物I 19.60±0.48
化合物Ⅱ 28.19±0.85
化合物Ⅲ 12.82±0.86
化合物Ⅳ 7.09±0.79
化合物Ⅴ 22.53±1.91
化合物Ⅵ 23.48±0.71
化合物Ⅶ 21.48±0.74
化合物Ⅷ 57.59±2.88
以上实施例的说明只是用于帮助理解本发明的方法及其核心思想。应当指出，对于本技术领域的普通技术人员来说，在不脱离本发明原理的前提下，还可以对本发明进行若干改进和修饰，这些改进和修饰也落入本发明权利要求的保护范围内。

Claims (10)

  1. 一种预防及治疗炎症的化合物，具有式Ⅰ～Ⅷ所示结构：
    Figure PCTCN2021083891-appb-100001
  2. 式I～Ⅷ所示化合物的制备方法，包括：
    步骤1：将丝沉香粉碎后，以体积分数不低于95％的乙醇水溶液超声提取，所得浸提液过滤后合并浓缩得浸膏A；
    步骤2：将所述浸膏A加水制成混悬液，依次用乙酸乙酯和正丁醇进行萃取，将乙酸乙酯萃取液浓缩制成浸膏B，正丁醇萃取液浓缩制成浸膏C；
    步骤3：取浸膏B，过减压柱，经石油醚、乙酸乙酯以及氯仿、甲醇的混合液梯度洗脱，获得19个流分，记为Fr.1～Fr.19；
    步骤4：取Fr.11，过葡聚糖凝胶柱，以甲醇：氯仿＝1：1的混合液进行洗脱，得到3个流份，记为Fr.11-1～Fr.11-3；
    步骤5：取Fr.11-2，过反相柱，以30％～100％甲醇水溶液梯度洗脱，得到30个流份，记为Fr.11-2-1～Fr.11-2-30；
    步骤6：取Fr.11-2-1，经半制备HPLC纯化，得到式Ⅷ化合物；
    步骤7：取Fr.13，过MCI柱，以30％～100％甲醇水溶液梯度洗脱，得到4个流份，记为Fr.13-1～Fr.13-4；
    步骤8：取Fr.13-1，过反相柱，以30％～100％甲醇水溶液梯度洗脱，得到15个流份，记为Fr.13-1-1～Fr.13-1-15；
    步骤9：取Fr.13-1-8，过葡聚糖凝胶柱，以甲醇进行洗脱，得到4个流份，记为Fr.13-1-8-1～Fr.13-1-8-4；
    步骤10：取Fr.13-1-8-4，过硅胶柱，以氯仿：乙酸乙酯梯度洗脱，得到5个流份，记为Fr.13-1-8-4-1～Fr.13-1-8-4-5；
    步骤11：取Fr.13-1-8-4-1，经半制备HPLC纯化，得到式Ⅴ化合物；
    步骤12：取Fr.13-1-8-4-2，经半制备HPLC纯化，得到式Ⅲ化合物；
    步骤13：取Fr.13-1-7，过葡聚糖凝胶柱，以甲醇进行洗脱，得到4个流份，记为Fr.13-1-7-1～Fr.13-1-7-4；
    步骤14：取Fr.13-1-7-4，过硅胶柱，以石油醚：乙酸乙酯梯度洗脱，得到6个流份，记为Fr.13-1-7-4-1～Fr.13-1-7-4-6；
    步骤15：取Fr.13-1-7-4-1，经半制备HPLC纯化，得到式Ⅳ化合物；
    步骤16：取Fr.13-1-10，过葡聚糖凝胶柱，以甲醇：氯仿＝1：1的混合液进行洗脱，得到5个流份，记为Fr.13-1-10-1～Fr.13-1-10-5；
    步骤17：取Fr.13-1-10-5，过硅胶柱，以石油醚：乙酸乙酯梯度洗脱得到22个流份，记为Fr.13-1-10-5-1～Fr.13-1-10-5-22；
    步骤18：取Fr.13-1-10-5-16，经半制备HPLC纯化，得到式Ⅶ化合物；
    步骤19：取Fr.13-1-10-4，过葡聚糖凝胶柱，以甲醇进行洗脱，得到3个流份，记为Fr.13-1-10-4-1～Fr.13-1-10-4-3；
    步骤20：取Fr.13-1-10-4-2，过硅胶柱，以氯仿：甲醇梯度洗脱得到15个流份，记为Fr.13-1-10-4-2-1～Fr.13-1-10-4-2-15；
    步骤21：取Fr.13-1-10-4-2-7，经半制备HPLC纯化，得到式Ⅰ化合物；
    步骤22：取Fr.15，过反相柱，以30％～100％甲醇水溶液梯度洗脱，得到45个流份，记为Fr.15-1～Fr.15-45；
    步骤23：取Fr.15-20，过葡聚糖凝胶柱，以甲醇进行洗脱，得到3个流份，记为Fr.15-20-1～Fr.15-20-3；
    步骤24：取Fr.15-20-3，经半制备HPLC纯化，得到式Ⅵ化合物；
    步骤25：取Fr.15-17，过葡聚糖凝胶柱，以甲醇进行洗脱，得到2个流份，记为Fr.15-17-1～Fr.15-17-2；
    步骤26：取Fr.15-17-2，经硅胶柱，以氯仿：乙酸乙酯梯度洗脱，得到7个流份，记为Fr.15-17-2-1～Fr.15-17-2-7；
    步骤27：取Fr.15-17-2-5，经半制备HPLC纯化，得到式Ⅱ化合物。
  3. 权利要求1所述的化合物或权利要求2所述的制备方法制备的化合物抑制产生促炎因子的应用。
  4. 根据权利要求3所述的应用，其特征在于，所述促炎因子包括肿瘤坏死因子、白细胞介素、前列腺素、一氧化氮、活性氧中的一种或多种。
  5. 权利要求1所述的化合物或权利要求2所述的制备方法制备的化合物作为NO生成抑制剂的应用。
  6. 权利要求1所述的化合物或权利要求2所述的制备方法制备的化合物在制备预防、治疗或缓解炎症或炎症反应的药物中的应用。
  7. 根据权利要求6所述的应用，其特征在于，所述炎症反应包括：机体发红、肿胀、发热、疼痛中的一种或多种。
  8. 一种预防、治疗或缓解炎症或炎症反应的药物，包括式Ⅰ～Ⅷ所示化合物中的一个或多个，以及药学上可接受的辅剂；
    Figure PCTCN2021083891-appb-100002
  9. 根据权利要求8所述的药物，其特征在于，所述药物的剂型为片剂、胶囊剂、丸剂、颗粒剂、汤剂、膏剂、露剂、口服液剂、滴丸剂或糖浆剂。
  10. 一种预防、治疗或缓解炎症或炎症反应的食品，包括式Ⅰ～Ⅷ所示化合物中的一个或多个；
    Figure PCTCN2021083891-appb-100003
PCT/CN2021/083891 2021-01-27 2021-03-30 一种预防及治疗炎症的化合物及其制备方法和应用 WO2022160455A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3120117A CA3120117C (en) 2021-01-27 2021-03-30 Compounds for preventing and treating inflammation, preparation method and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110113002.1 2021-01-27
CN202110113002.1A CN112898261B (zh) 2021-01-27 2021-01-27 一种预防及治疗炎症的化合物及其制备方法和应用

Publications (1)

Publication Number Publication Date
WO2022160455A1 true WO2022160455A1 (zh) 2022-08-04

Family

ID=76119005

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/083891 WO2022160455A1 (zh) 2021-01-27 2021-03-30 一种预防及治疗炎症的化合物及其制备方法和应用

Country Status (2)

Country Link
CN (1) CN112898261B (zh)
WO (1) WO2022160455A1 (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115260258A (zh) * 2022-09-13 2022-11-01 贵州医科大学 一种原苏木素B-3-O-β-D-葡萄糖苷及其制备方法与应用
CN116715707A (zh) * 2023-06-07 2023-09-08 齐齐哈尔医学院 白鲜酚苷d及其制备方法和应用
CN116789657A (zh) * 2023-06-21 2023-09-22 自然资源部第三海洋研究所 一种具有抗炎活性的化合物及其提取分离方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106309423A (zh) * 2015-07-09 2017-01-11 北京中医药大学 沉香中氯代四氢苯乙基色酮衍生物及其药物组合物的用途
JP2017088571A (ja) * 2015-11-13 2017-05-25 学校法人慶應義塾 ホスホジエステラーゼ阻害剤、医薬組成物、飲食品、化粧品、及び２−〔２−（４−メトキシフェニル）エチル〕クロモン誘導体
CN107034252A (zh) * 2016-02-03 2017-08-11 北京中医药大学 一种诱导白木香愈伤细胞产生2-(2-苯乙基)色酮类成分的方法
CN110818669A (zh) * 2019-11-25 2020-02-21 中国医学科学院药用植物研究所海南分所 沉香四氢2-（2-苯乙基）色酮类化合物及其分离方法和应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106309423A (zh) * 2015-07-09 2017-01-11 北京中医药大学 沉香中氯代四氢苯乙基色酮衍生物及其药物组合物的用途
JP2017088571A (ja) * 2015-11-13 2017-05-25 学校法人慶應義塾 ホスホジエステラーゼ阻害剤、医薬組成物、飲食品、化粧品、及び２−〔２−（４−メトキシフェニル）エチル〕クロモン誘導体
CN107034252A (zh) * 2016-02-03 2017-08-11 北京中医药大学 一种诱导白木香愈伤细胞产生2-(2-苯乙基)色酮类成分的方法
CN110818669A (zh) * 2019-11-25 2020-02-21 中国医学科学院药用植物研究所海南分所 沉香四氢2-（2-苯乙基）色酮类化合物及其分离方法和应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GAO MEI, XIAOMIN HAN, JUNQING HUANG, YING SUN, YANGYANG LIU, HONGJIANG CHEN, YUE JIN, YUN YANG, ZHIHUI GAO, YANHONG XU, ZHENG ZHAN: "Simultaneous Determination of Multiple Active 2-(2-Phenylethyl)Chromone Analogues in Agarwood by HPLC, QAMS, and UPLC-MS", PHYTOCHEMICAL ANALYSIS, vol. 32, no. 3, 16 September 2020 (2020-09-16), pages 412 - 422, XP055954946, DOI: 10.1002/pca.2989 *
SHAO HANG, MEI WEN-LI, DONG WEN-HUA, GAI CUI-JUAN, LI WEI, ZHU GUO-PENG, DAI HAO-FU: "2-(2-Phenylethyl)chromone Derivatives of Agarwood Originating from Gyrinops salicifolia", MOLECULES, vol. 21, no. 10, 3 October 2016 (2016-10-03), pages 1313, XP055954948, DOI: 10.3390/molecules21101313 *
WANG SIN-LING, HWANG TSONG-LONG, CHUNG MEI-ING, SUNG PING-JYUN, SHU CHIH-WEN, CHENG MING-JEN, CHEN JIH-JUNG: "New Flavones, a 2-(2-Phenylethyl)-4H-chromen-4-one Derivative, and Anti-Inflammatory Constituents from the Stem Barks of Aquilaria sinensis", MOLECULES, vol. 20, no. 11, 24 November 2015 (2015-11-24), pages 20912 - 20925, XP055954945, DOI: 10.3390/molecules201119736 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115260258A (zh) * 2022-09-13 2022-11-01 贵州医科大学 一种原苏木素B-3-O-β-D-葡萄糖苷及其制备方法与应用
CN116715707A (zh) * 2023-06-07 2023-09-08 齐齐哈尔医学院 白鲜酚苷d及其制备方法和应用
CN116715707B (zh) * 2023-06-07 2024-02-02 齐齐哈尔医学院 白鲜酚苷d及其制备方法和应用
CN116789657A (zh) * 2023-06-21 2023-09-22 自然资源部第三海洋研究所 一种具有抗炎活性的化合物及其提取分离方法和应用
CN116789657B (zh) * 2023-06-21 2024-05-07 自然资源部第三海洋研究所 一种具有抗炎活性的化合物及其提取分离方法和应用

Also Published As

Publication number Publication date
CN112898261A (zh) 2021-06-04
CN112898261B (zh) 2023-06-06

Similar Documents

Publication Publication Date Title
WO2022160455A1 (zh) 一种预防及治疗炎症的化合物及其制备方法和应用
CN110372731B (zh) 喹啉-白坚木碱型双吲哚生物碱类化合物及其应用
CN111253460B (zh) 一种具有抗炎活性的三萜类药物及其制备方法和应用
CN111704544B (zh) 一种半日花烷型二萜类化合物及其分离方法和应用
CN113754533A (zh) 氧化半日花烷型二萜类化合物及其分离方法和应用
CN111349017A (zh) 一种从金钗石斛中提取化合物的工艺及应用
CN111377994A (zh) 七种来源于灯笼果的醉茄内酯类化合物及其制备方法和用途
CN107056869B (zh) 一种睡茄交酯类化合物及提取方法及应用
CN111018877B (zh) 一种土木香中倍半萜类衍生物、其制备方法及应用
CN102219782B (zh) 一种从天然产物中提取分离牡荆素和异牡荆素的方法
CN115340512B (zh) 水母雪莲中三种二芳基丁内酯型木脂素类化合物及其提取分离方法和应用
CN113582951A (zh) 10-(s)-17-氢-7-去氢穿心莲内酯及其工业色谱制备方法和用途
CN114213375B (zh) 一种倍半萜内酯化合物及其制备方法与应用
Li et al. Triterpenoid saponins from Psammosilene tunicoides and their antinociceptive activities
CN114933602A (zh) 白花地胆草中高度氧化的吉玛烷型倍半萜内酯类化合物及其制备方法和应用
CA3120117C (en) Compounds for preventing and treating inflammation, preparation method and use thereof
CN110437198B (zh) 倍半萜类化合物及其应用
CN110746387B (zh) 克罗烷型二萜衍生物、制备方法及其抗炎药物或炎症反应抑制剂
CN109180632B (zh) 一种从雷公藤中分离出的化合物的制备方法
CN110452278B (zh) 臭七次生代谢物及其制备方法与其在制药中的应用
CN106749158A (zh) 一种苝醌类化合物及其制备方法和用途
CN115433152B (zh) 从金丝梅果实内分离出的化合物、制备方法和用途
CN112920146B (zh) 倍半萜类化合物及其制备方法和在制备抗炎药物中的应用
CN115160114B (zh) 水母雪莲中五种芳基萘型木脂素类化合物及其提取分离方法和应用
CN114478683B (zh) 一种球蕊五味子内酯a及其制备与应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21922054

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21922054

Country of ref document: EP

Kind code of ref document: A1